Companies with positive PBAC recommendations from November are already dealing with the indirect consequences of next April and it is just one of the challenges facing pharmaceutical, medical device and diagnostic companies as we look forward to 2023.
Next year will be even tougher unless the downward trajectory can be halted
December 8, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Week in Review' - 27 January
January 27, 2023 - - Podcast -
Forget about experts and terms of reference until we get a transparent process
January 27, 2023 - - Latest News -
Australia Day recognition for senior officials and pharmacy leaders
January 27, 2023 - - Latest News -
Is this a change of heart from the former health department secretary?
January 27, 2023 - - Latest News -
New chair for Australian genomics industry organisation
January 26, 2023 - - Australian Biotech -
MEDLAB receives Import Certificate from UK Home Office for NanaBis
January 26, 2023 - - Australian Biotech -
Alterity Therapeutics launches ATH434 Phase 2 clinical trial in Italy
January 26, 2023 - - Australian Biotech